Mutlu Hayran
Impact in
- Otorhinolaryngology top 5%
- Head and Neck Cancer Studies
- Oncology top 5%
- Drug Transport and Resistance Mechanisms
- Inflammatory Biomarkers in Disease Prognosis
Papers in
- Co-authors
- Başak Yalçın (4 shared papers)Ömer Dızdar (14 shared papers)Nuran Allı (2 shared papers)Sercan Aksoy (8 shared papers)Pınar Öztaş (1 shared paper)Emine Tamer (1 shared paper)Hakan Harputluoğlu (3 shared papers)Ömrüm Uzun (3 shared papers)
- Journals
- Journal of Clinical Oncology (7 papers)Medical Oncology (4 papers)Clinical Rheumatology (3 papers)Pediatric Nephrology (3 papers)Antimicrobial Agents and Chemotherapy (2 papers)
- Partner nations
- TürkiyeUnited StatesSpain
In The Last Decade
Mutlu Hayran
144 papers receiving 2.8k citations
Peers
Comparison fields: 5 of 136
- Otorhinolaryngology 119
- Oncology 536
- Periodontics 74
- Dermatology 140
- Immunology and Allergy 74
Countries citing papers authored by Mutlu Hayran
This map shows the geographic impact of Mutlu Hayran's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Mutlu Hayran with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Mutlu Hayran more than expected).
Fields of papers citing papers by Mutlu Hayran
This network shows the impact of papers produced by Mutlu Hayran. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Mutlu Hayran. The network helps show where Mutlu Hayran may publish in the future.
Co-authors
The 25 scholars most cited alongside Mutlu Hayran, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
Showing the 20 most-cited of 152 papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | 2005 | 173 | |
| 2 | 2007 | 97 | |
| 3 | 2009 | 94 | |
| 4 | 1993 | 85 | |
| 5 | 2009 | 80 | |
| 6 | Clinical validation of the influence of P-glycoprotein on technetium-99m-sestamibi uptake in malignant tumors. | 1997 | 74 |
| 7 | Association of tumor washout rates and accumulation of technetium-99m-MIBI with expression of P-glycoprotein in lung cancer. | 1998 | 68 |
| 8 | 1999 | 64 | |
| 9 | Association of drug transporter gene ABCB1 (MDR1) 3435C to T polymorphism with colchicine response in familial Mediterranean fever. | 2007 | 62 |
| 10 | 2010 | 62 | |
| 11 | 2008 | 60 | |
| 12 | 2007 | 57 | |
| 13 | 2011 | 55 | |
| 14 | 2002 | 54 | |
| 15 | 2007 | 50 | |
| 16 | 2017 | 50 | |
| 17 | 2007 | 46 | |
| 18 | 2006 | 44 | |
| 19 | 2011 | 43 | |
| 20 | 2009 | 43 |
About Mutlu Hayran
Mutlu Hayran is a scholar working on Oncology, Surgery, Pulmonary and Respiratory Medicine, Pathology and Forensic Medicine and Physiology, having authored 152 papers that have together received 2.9k indexed citations. Recurring topics across this work include Smoking Behavior and Cessation (8 papers), Cancer Treatment and Pharmacology (7 papers), Head and Neck Cancer Studies (5 papers), Lymphoma Diagnosis and Treatment (5 papers), Breast Cancer Treatment Studies (4 papers), Autoimmune and Inflammatory Disorders Research (4 papers), Global Cancer Incidence and Screening (4 papers) and Brain Metastases and Treatment (4 papers). The work is most often cited by research in Otorhinolaryngology (119 citations), Oncology (536 citations), Periodontics (74 citations), Dermatology (140 citations) and Immunology and Allergy (74 citations). Mutlu Hayran has collaborated with scholars based in Türkiye, United States and Spain. Frequent co-authors include Başak Yalçın, Ömer Dızdar, Nuran Allı, Sercan Aksoy, Pınar Öztaş, Emine Tamer, Hakan Harputluoğlu, Ömrüm Uzun, Gülnur Güler and Serhat Ünal. Their work appears in journals such as Journal of Clinical Oncology, Medical Oncology, Clinical Rheumatology, Pediatric Nephrology and Antimicrobial Agents and Chemotherapy.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.